Vertex
NICE Recommends Vertex, CRISPR Therapeutics' Casgevy for Sickle Cell Under Managed Access Deal
The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.
HHS Calls Vertex's Case for Fertility Program a 'Distraction,' Urges Court to Rule in Its Favor
HHS is asking the court to affirm its Office of Inspector General's finding that paying for fertility services would run afoul of anti-kickback laws.
Vertex Gains Rights to Orna Therapeutics' Drug Delivery Tech in $1.07B Deal
Vertex aims to further bolster its gene-editing therapy pipeline by using Orna's lipid nanoparticle delivery technologies during the three-year collaboration.
FDA Approves New 'Vanza Triple' Cystic Fibrosis Drug From Vertex, Expands Label for Trikafta
Alyftrek is approved as a new treatment for cystic fibrosis, while the FDA expanded the label for Trikafta to include additional genetic mutations.
The FDA approved three new gene therapy products in 2024 and expanded indications for two others, all for rare diseases.